No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation

BackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A a...

Full description

Bibliographic Details
Main Authors: Rong Hu, Daniel T. Barratt, Janet K. Coller, Benedetta C. Sallustio, Andrew A. Somogyi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01686/full
id doaj-09f5dab800634c7eb84f26678c393ba0
record_format Article
spelling doaj-09f5dab800634c7eb84f26678c393ba02020-11-25T00:18:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-02-011010.3389/fphar.2019.01686504610No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-TransplantationRong Hu0Daniel T. Barratt1Janet K. Coller2Benedetta C. Sallustio3Benedetta C. Sallustio4Andrew A. Somogyi5Andrew A. Somogyi6Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDepartment of Clinical Pharmacology, The Queen Elizabeth Hospital, Adelaide, SA, AustraliaDiscipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide, SA, AustraliaDepartment of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, SA, AustraliaBackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A are not associated with acute rejection incidence in Caucasian kidney transplant recipients receiving a calcineurin inhibitor, ciclosporin or tacrolimus (TAC). However, other important innate immune genetic polymorphisms have not yet been extensively studied in recipients and donors. In addition, innate immunogenetics have not been investigated in kidney transplant cohorts receiving only TAC as the calcineurin inhibitor.ObjectiveTo investigate the effect of recipient and donor CASP1, CRP, IL1B, IL2, IL6, IL6R, IL10, MYD88, TGFB, TLR2, TLR4, and TNF genetics on acute kidney rejection in the first 2 weeks post-transplant in TAC-treated kidney transplant recipients.MethodsThis study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores.ResultsA trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient IL6 -6331 T/T (18%) to T/C (25%) to C/C (46%) genotype [C/C versus T/T odds ratio (95% confidence interval) = 6.6 (1.7 to 25.8) (point-wise P = 0.017)]. However, no genotype differences were significant after Bonferroni correction for multiple comparisons.ConclusionsThis study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as IL6 influence the risk of acute rejection after kidney transplantation.https://www.frontiersin.org/article/10.3389/fphar.2019.01686/fulltacrolimusimmune geneticskidney transplantationacute rejectionIL6 -6331
collection DOAJ
language English
format Article
sources DOAJ
author Rong Hu
Daniel T. Barratt
Janet K. Coller
Benedetta C. Sallustio
Benedetta C. Sallustio
Andrew A. Somogyi
Andrew A. Somogyi
spellingShingle Rong Hu
Daniel T. Barratt
Janet K. Coller
Benedetta C. Sallustio
Benedetta C. Sallustio
Andrew A. Somogyi
Andrew A. Somogyi
No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
Frontiers in Pharmacology
tacrolimus
immune genetics
kidney transplantation
acute rejection
IL6 -6331
author_facet Rong Hu
Daniel T. Barratt
Janet K. Coller
Benedetta C. Sallustio
Benedetta C. Sallustio
Andrew A. Somogyi
Andrew A. Somogyi
author_sort Rong Hu
title No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
title_short No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
title_full No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
title_fullStr No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
title_full_unstemmed No Major Effect of Innate Immune Genetics on Acute Kidney Rejection in the First 2 Weeks Post-Transplantation
title_sort no major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-02-01
description BackgroundInnate immunity contributes to acute rejection after kidney transplantation. Genetic polymorphisms affecting innate immunity may therefore influence patients’ risk of rejection. IL2 -330T > G, IL10 -1082G > A, -819C > T, and -592C > A, and TNF -308G > A are not associated with acute rejection incidence in Caucasian kidney transplant recipients receiving a calcineurin inhibitor, ciclosporin or tacrolimus (TAC). However, other important innate immune genetic polymorphisms have not yet been extensively studied in recipients and donors. In addition, innate immunogenetics have not been investigated in kidney transplant cohorts receiving only TAC as the calcineurin inhibitor.ObjectiveTo investigate the effect of recipient and donor CASP1, CRP, IL1B, IL2, IL6, IL6R, IL10, MYD88, TGFB, TLR2, TLR4, and TNF genetics on acute kidney rejection in the first 2 weeks post-transplant in TAC-treated kidney transplant recipients.MethodsThis study included 154 kidney transplant recipients and 81 donors successfully genotyped for 17 polymorphisms in these genes. All recipients were under triple immunosuppressant therapy of TAC, mycophenolate mofetil, and prednisolone. Recipient and donor genotype differences in acute rejection incidence within the first 2 weeks post-transplantation were assessed by logistic regression, adjusting for induction therapy, human leukocyte antigen mismatches, kidney transplant number, living donor, and peak panel-reactive antibody scores.ResultsA trend (Cochran-Armitage P = 0.031) of increasing acute rejection incidence was observed from recipient IL6 -6331 T/T (18%) to T/C (25%) to C/C (46%) genotype [C/C versus T/T odds ratio (95% confidence interval) = 6.6 (1.7 to 25.8) (point-wise P = 0.017)]. However, no genotype differences were significant after Bonferroni correction for multiple comparisons.ConclusionsThis study did not detect any statistically significant effects of recipient or donor innate immune genetics on acute rejection incidence in the first 2 weeks post-transplantation. However, the sample size was small, and future larger studies or meta-analyses are required to demonstrate conclusively if innate immune genetics such as IL6 influence the risk of acute rejection after kidney transplantation.
topic tacrolimus
immune genetics
kidney transplantation
acute rejection
IL6 -6331
url https://www.frontiersin.org/article/10.3389/fphar.2019.01686/full
work_keys_str_mv AT ronghu nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT danieltbarratt nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT janetkcoller nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT benedettacsallustio nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT benedettacsallustio nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT andrewasomogyi nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
AT andrewasomogyi nomajoreffectofinnateimmunegeneticsonacutekidneyrejectioninthefirst2weeksposttransplantation
_version_ 1725375139763191808